GLP-1 shows promise for patients with advanced fatty liver disease. Researchers at the University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Researchers at the University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis.
- Ponto de atenção: shows.
- Ponto de atenção: promise.
- Ponto de atenção: patients.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/a1420573-3a46-4ee9-ba20-9297dce01005.png)
